Treatment with 5F9 induces macrophages to recognize and attack cancer cells by preventing the activation of the CD47-SIRPα axis and promoting the phagocytosis of tumor cells via innate immune cells [1, 27]. This evidence concerns the gene SIRPA and neoplasm.